John R. Lurain

No ORCID on file · 2 papers in corpus

lab-animal 2017

The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient derived xenografts of endometrial cancer

Cancer biology & therapy ·doi:10.1080/15384047.2017.1281496

The purpose of this study was to test the effect of MK2206, an allosteric inhibitor of AKT, on the growth and invasion of patient-derived xenografts (PDX) of endometrial cancer. Three PDX lines, USC1 (uterine serous), EEC2 (endometrioid gra…

other 2016

An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas

Journal of Minimally Invasive Gynecology ·doi:10.1016/j.jmig.2015.12.012